285 related articles for article (PubMed ID: 20556505)
1. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer.
Mahmoud SM; Paish EC; Powe DG; Macmillan RD; Lee AH; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 May; 127(1):99-108. PubMed ID: 20556505
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma.
Sasaki A; Tanaka F; Mimori K; Inoue H; Kai S; Shibata K; Ohta M; Kitano S; Mori M
Eur J Surg Oncol; 2008 Feb; 34(2):173-9. PubMed ID: 17928188
[TBL] [Abstract][Full Text] [Related]
4. Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients.
Liu F; Li Y; Ren M; Zhang X; Guo X; Lang R; Gu F; Fu L
Breast Cancer Res Treat; 2012 Sep; 135(2):459-67. PubMed ID: 22842982
[TBL] [Abstract][Full Text] [Related]
5. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
Ladoire S; Arnould L; Apetoh L; Coudert B; Martin F; Chauffert B; Fumoleau P; Ghiringhelli F
Clin Cancer Res; 2008 Apr; 14(8):2413-20. PubMed ID: 18413832
[TBL] [Abstract][Full Text] [Related]
6. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
7. The ratio of intra-tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer.
Kim HI; Kim H; Cho HW; Kim SY; Song KJ; Hyung WJ; Park CG; Kim CB
J Surg Oncol; 2011 Dec; 104(7):728-33. PubMed ID: 21792941
[TBL] [Abstract][Full Text] [Related]
8. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
[TBL] [Abstract][Full Text] [Related]
9. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
10. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma.
Hasselblom S; Sigurdadottir M; Hansson U; Nilsson-Ehle H; Ridell B; Andersson PO
Br J Haematol; 2007 May; 137(4):364-73. PubMed ID: 17456059
[TBL] [Abstract][Full Text] [Related]
11. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
[TBL] [Abstract][Full Text] [Related]
12. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
Giatromanolaki A; Bates GJ; Koukourakis MI; Sivridis E; Gatter KC; Harris AL; Banham AH
Gynecol Oncol; 2008 Aug; 110(2):216-21. PubMed ID: 18533240
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.
Badoual C; Hans S; Rodriguez J; Peyrard S; Klein C; Agueznay Nel H; Mosseri V; Laccourreye O; Bruneval P; Fridman WH; Brasnu DF; Tartour E
Clin Cancer Res; 2006 Jan; 12(2):465-72. PubMed ID: 16428488
[TBL] [Abstract][Full Text] [Related]
14. In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype.
Anz D; Eiber S; Scholz C; Endres S; Kirchner T; Bourquin C; Mayr D
Histopathology; 2011 Nov; 59(5):965-74. PubMed ID: 22092408
[TBL] [Abstract][Full Text] [Related]
15. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus.
Zingg U; Montani M; Frey DM; Dirnhofer S; Esterman AJ; Went P; Oertli D
Eur J Surg Oncol; 2010 Jul; 36(7):670-7. PubMed ID: 20510571
[TBL] [Abstract][Full Text] [Related]
16. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
[TBL] [Abstract][Full Text] [Related]
17. FOXP3 and survival in urinary bladder cancer.
Winerdal ME; Marits P; Winerdal M; Hasan M; Rosenblatt R; Tolf A; Selling K; Sherif A; Winqvist O
BJU Int; 2011 Nov; 108(10):1672-8. PubMed ID: 21244603
[TBL] [Abstract][Full Text] [Related]
18. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer.
Aruga T; Suzuki E; Saji S; Horiguchi S; Horiguchi K; Sekine S; Kitagawa D; Funata N; Toi M; Sugihara K; Kuroi K
Oncol Rep; 2009 Aug; 22(2):273-8. PubMed ID: 19578766
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis.
Gupta S; Joshi K; Wig JD; Arora SK
Acta Oncol; 2007; 46(6):792-7. PubMed ID: 17653902
[TBL] [Abstract][Full Text] [Related]
20. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
